- Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom — Recruiting • Oncology • NCT05557695.
- What is being tested: Real-world clinical outcomes and patient characteristics of acalabrutinib (a Bruton tyrosine kinase inhibitor) in UK patients with chronic lymphocytic leukaemia through retrospective observational analysis (EPIC study).
- Patient eligibility overview: UK patients with chronic lymphocytic leukaemia receiving acalabrutinib treatment, recruited through physicians actively managing these patients in routine clinical practice.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study). Physicians treating chronic lymphocytic leukaemia patients with acalabrutinib, where the patients started treatment as part of the acalabrutinib Early Access Programme (EAP), will be invited to recruit patients. Clinical data will be extracted from the patients' clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients who were started on acalabrutinib as…
- The study population will include treatment-naïve patients with chronic lymphocytic lymphoma (CLL)* who meet the following inclusion criteria: * Treatment-naïve CLL patients who were initiated on acalabrutinib as part of the UK Early Access Programme * Received their first dose of acalabrutinib between 1 April 2020 and 1 April 2021 * Patients aged ≥18 years old * Note: patients later found to have small lymphocytic lymphoma (SLL) may also be included in the EAP.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.